Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.

杜瓦卢马布 银耳霉素 吉西他滨 医学 内科学 顺铂 化疗 肿瘤科
作者
Do-Youn Oh,Kyung-Hun Lee,Dae-Won Lee,Jeesun Yoon,Tae-Yong Kim,Ju-Hee Bang,Ah-Rong Nam,Kyoung-Seok Oh,Jae-Min Kim,Young Lee,Violeta Guthrie,Patricia McCoon,Weimin Li,Song Wu,Qu Zhang,Marlon C Rebelatto,Jin Won Kim
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:7 (6): 522-532
标识
DOI:10.1016/s2468-1253(22)00043-7
摘要

Immunotherapies have shown clinical activity in patients with advanced biliary tract cancer, for which outcomes remain poor despite standard of care treatment with gemcitabine and cisplatin. We aimed to evaluate gemcitabine and cisplatin plus durvalumab with or without tremelimumab as first-line treatment in patients with advanced biliary tract cancer.This open-label, single-centre, phase 2 study was conducted at Seoul National University Hospital. Eligible patients were treatment-naïve adults aged 18 years or older with histologically proven unresectable or recurrent biliary tract cancer, at least one measurable lesion based on the Response Evaluation Criteria in Solid Tumors (version 1.1), an Eastern Cooperative Oncology Group performance status of 0 or 1, life expectancy of 12 weeks or longer, and adequate healthy organ and bone marrow function. Initially, all patients received one 3-week cycle of gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2) on day 1 and 8 followed by gemcitabine and cisplatin plus durvalumab (1120 mg) and tremelimumab (75 mg) on day 1 of each cycle, starting with the second cycle (chemotherapy followed by chemotherapy plus durvalumab and tremelimumab group). Following protocol amendment, patients were recruited to receive gemcitabine and cisplatin plus durvalumab, starting on day 1 of the first cycle (chemotherapy plus durvalumab group) or gemcitabine and cisplatin plus durvalumab and tremelimumab also from day 1 of the first cycle (chemotherapy plus durvalumab and tremelimumab group) in parallel and allocated using a random block method. Assessors and patients were not masked to the treatment group. The primary endpoint was objective response rate, assessed in the efficacy population (ie, patients who were treated at least until the first tumour response assessment). This study is registered with ClinicalTrials.gov, NCT03046862 (active).Between March 2, 2017, and Feb 13, 2020, 128 patients were enrolled (32 in the chemotherapy followed by chemotherapy plus durvalumab and tremelimumab group, 49 in the chemotherapy plus durvalumab group, and 47 in the chemotherapy plus durvalumab and tremelimumab group). Four patients (two in the chemotherapy followed by chemotherapy plus durvalumab and tremelimumab group and two in the chemotherapy plus durvalumab group) were excluded and 124 were evaluable for tumour response. The median duration of follow-up was 48·2 months (IQR 41·5-49·4) for the chemotherapy followed by chemotherapy plus durvalumab and tremelimumab group, 26·6 months (19·0-27·9) for the chemotherapy plus durvalumab group, and 24·2 months (20·7-31·7) for the chemotherapy plus durvalumab and tremelimumab group. 82 (66%) of 124 patients achieved an objective response (15 [50%] of 30 in the chemotherapy followed by chemotherapy plus durvalumab and tremelimumab group, 34 [72%] of 47 in the chemotherapy plus durvalumab group, and 33 [70%] of 47 in the chemotherapy plus durvalumab and tremelimumab group). The most common grade 3 and 4 adverse events were decreased neutrophil count (67 [53%] of 126), anaemia (50 [40%]), and decreased platelet count (24 [19%]), with no unexpected safety events. No adverse events leading to discontinuation or death occurred.Gemcitabine and cisplatin plus immunotherapy showed promising efficacy and acceptable safety in patients with biliary tract cancer. Gemcitabine and cisplatin plus durvalumab are being evaluated in the phase 3, TOPAZ-1 study (NCT03875235) as first-line treatment in patients with advanced biliary tract cancer.AstraZeneca; National Research Foundation of Korea (Grant No. 2021R1A2C2007430).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Lyuhng+1完成签到 ,获得积分10
2秒前
内向雨南发布了新的文献求助10
3秒前
渔渔发布了新的文献求助10
4秒前
Kk完成签到 ,获得积分10
4秒前
6秒前
心灵美砖头完成签到,获得积分10
7秒前
刚子完成签到 ,获得积分0
8秒前
junmahmu完成签到,获得积分10
8秒前
阿俊1212发布了新的文献求助10
9秒前
xlk2222完成签到,获得积分10
13秒前
Silieze完成签到,获得积分10
14秒前
沉醉完成签到 ,获得积分10
15秒前
无辜的蜗牛完成签到 ,获得积分10
16秒前
零玖完成签到 ,获得积分10
17秒前
17秒前
gao高完成签到,获得积分10
21秒前
灵巧一笑完成签到 ,获得积分10
22秒前
小可乐完成签到,获得积分10
23秒前
认真初之完成签到,获得积分10
24秒前
隐形曼青应助祯果粒采纳,获得10
26秒前
lyb完成签到 ,获得积分10
26秒前
LaTeXer给踹脸大妈的求助进行了留言
28秒前
渔渔完成签到,获得积分10
31秒前
JinGN完成签到,获得积分10
32秒前
骑驴追火箭完成签到,获得积分10
32秒前
Fjj完成签到,获得积分10
32秒前
35秒前
闾丘剑封发布了新的文献求助10
35秒前
小胖子完成签到 ,获得积分10
35秒前
36秒前
沙洲完成签到 ,获得积分10
37秒前
38秒前
双楠完成签到,获得积分10
38秒前
搞怪人雄完成签到,获得积分10
38秒前
祯果粒发布了新的文献求助10
40秒前
41秒前
鼠鼠完成签到 ,获得积分10
42秒前
独自受罪完成签到 ,获得积分10
42秒前
风笛完成签到 ,获得积分10
43秒前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 370
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3991055
求助须知:如何正确求助?哪些是违规求助? 3532313
关于积分的说明 11256902
捐赠科研通 3271211
什么是DOI,文献DOI怎么找? 1805344
邀请新用户注册赠送积分活动 882304
科研通“疑难数据库(出版商)”最低求助积分说明 809252